Key facts
- Aimedbio’s last known valuation is $482.2M (Dec 2025).
- It has raised $85.1M; the latest was IPO ($48.3M) in Dec 2025.
- Status: Publicly Held.
- ·Watchlist + deal alerts for Aimedbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Aimedbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aimedbio
Operator of a healthcare company intended to serve patients with serious brain diseases. The company provides therapeutic systems and medicines for neuro-oncological and degenerative diseases, enabling patients with refractory brain disease, including cancer, to have an improved quality of life.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 50
- Website
- aimedbio.com/
- Ownership
- Publicly Held
Aimedbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aimedbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aimedbio in its N-PORT filings yet. We sweep new filings monthly.